New product intros [anamorelin hydrochloride, casimersen, loncastuximab tesirine, dapagliflozin (new indication), molidustat sodium, mometasone furoate/azelastine hydrochloride (new combination), OTL-200, setmelanotide, umbralisib tosylate (first-in-class), vericiguat]

{"title":"New product intros [anamorelin hydrochloride, casimersen, loncastuximab tesirine, dapagliflozin (new indication), molidustat sodium, mometasone furoate/azelastine hydrochloride (new combination), OTL-200, setmelanotide, umbralisib tosylate (first-in-class), vericiguat]","authors":"","doi":"10.1358/dot.2021.57.6.3317998","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2021.57.6.3317998","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
新产品介绍[盐酸阿那莫瑞林、卡西莫森、loncastuximab tesirine、达格列净(新适应症)、莫度他钠、糠酸莫米松/盐酸氮唑来汀(新组合)、OTL-200、setmelanotide、umbralisib tosylate(同类首创)、vericiguat]
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信